Immunotherapy in Glioblastoma: A Clinical Perspective.

Détails

Ressource 1Télécharger: 34359621_BIB_89F18E1BB4ED.pdf (1047.23 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_89F18E1BB4ED
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immunotherapy in Glioblastoma: A Clinical Perspective.
Périodique
Cancers
Auteur(s)
Desbaillets N., Hottinger A.F.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Statut éditorial
Publié
Date de publication
24/07/2021
Peer-reviewed
Oui
Volume
13
Numéro
15
Pages
3721
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Glioblastoma is the most frequent and the most aggressive brain tumor. It is notoriously resistant to current treatments, and the prognosis remains dismal. Immunotherapies have revolutionized the treatment of numerous cancer types and generate great hope for glioblastoma, alas without success until now. In this review, the rationale underlying immune targeting of glioblastoma, as well as the challenges faced when targeting these highly immunosuppressive tumors, are discussed. Innovative immune-targeting strategies including cancer vaccines, oncolytic viruses, checkpoint blockade inhibitors, adoptive cell transfer, and CAR T cells that have been investigated in glioblastoma are reviewed. From a clinical perspective, key clinical trial findings and ongoing trials are discussed for each approach. Finally, limitations, either biological or arising from trial designs are analyzed, and strategies to overcome them are presented. Proof of efficacy for immunotherapy approaches remains to be demonstrated in glioblastoma, but our rapidly expanding understanding of its biology, its immune microenvironment, and the emergence of novel promising combinatorial approaches might allow researchers to finally fulfill the medical need for GBM patients.
Mots-clé
CAR T cell, checkpoint inhibitor, glioblastoma, immunotherapy, oncolytic virus, vaccine
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/08/2021 14:14
Dernière modification de la notice
12/01/2022 7:11
Données d'usage